Zai Lab Ltd (ZLAB) stock

ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30471% above fair value

$24.60−1.44 (-5.53%)

Close on Nov 13, 2026Market cap $3.82BP/E –Yield –

Earnings

Zai Lab's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 25, 2027

Q4 FY2026 · estimated, before the open

Revenue, Q3 FY2026

$108.20M

-6.8% on a year earlier

Adjusted EPS, Q3 FY2026

-$0.04

-$0.03 a year earlier

Latest guidance

Issued

Nov 6, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Zai Lab's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 25, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 5, 2026before the open	$108.20M	-6.8%	-$0.04	–	Release
Q2 FY2026ended Jun 30, 2026	Aug 6, 2026before the open	$106.30M	-3.4%	-$0.05	–	Release
Q1 FY2026ended Mar 31, 2026	May 7, 2026before the open	$99.60M	-6.5%	-$0.05	–	Release
Q4 FY2025ended Dec 31, 2025	Feb 26, 2026before the open	$127.60M	+17.0%	-$0.05	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 6, 2025before the open	$116.10M	–	-$0.03	–	Release
Q2 FY2025ended Jun 30, 2025	Aug 7, 2025before the open	$110.00M	+9.9%	–	-$0.04	Release
Q1 FY2025ended Mar 31, 2025	May 8, 2025before the open	$106.50M	+22.3%	–	–	Release
Q4 FY2024ended Dec 31, 2024	Feb 27, 2025before the open	$109.10M	–	-$0.08	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 12, 2024before the open	–	–	–	–	Release
Q2 FY2024ended Jun 30, 2024	Aug 6, 2024after the close	$100.10M	+45.3%	-$0.08	–	Release
Q1 FY2024ended Mar 31, 2024	May 8, 2024after the close	$87.10M	+38.7%	-$0.05	–	Release
Q4 FY2023ended Dec 31, 2023	Feb 27, 2024after the close	–	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 7, 2023after the close	$69.20M	+20.3%	-$0.07	–	Release
Q2 FY2023ended Jun 30, 2023	Aug 7, 2023after the close	$68.90M	+42.9%	-$0.13	–	Release
Q1 FY2023ended Mar 31, 2023	May 9, 2023after the close	$62.80M	+34.5%	-$0.05	–	Release
Q4 FY2022ended Dec 31, 2022	Mar 1, 2023after the close	$62.60M	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 9, 2022after the close	$57.50M	–	-$0.17	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 9, 2022after the close	$48.20M	–	-$0.14	–	Release
Q1 FY2022ended Mar 31, 2022	May 10, 2022after the close	$46.70M	–	-$0.09	–	Release
Q4 FY2021ended Dec 31, 2021	Mar 1, 2022after the close	–	–	–	–	Release
Q3 FY2021ended Sep 30, 2021	Nov 9, 2021after the close	–	–	–	–	Release
Q2 FY2021ended Jun 30, 2021	Aug 9, 2021after the close	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	May 10, 2021before the open	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Mar 1, 2021before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Zai Lab guided for has been reported

Guidance vs results

The last range Zai Lab gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Revenue	$460.00M	$460.20MΣ4Q	Within range

Guidance history

Every forecast Zai Lab put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Nov 6, 2025	total revenue	FY2025	$460.00M	New
Aug 7, 2025	revenue	FY2025	$560.00M – $590.00M	Reaffirmed
May 8, 2025	revenue	FY2025	$560.00M – $590.00M	Reaffirmed
Feb 27, 2025	Total revenue	FY2025	$560.00M – $590.00M	New
Aug 6, 2024	VYVGART revenue	FY2024	$80.00M	Raised
Feb 27, 2024	VYVGART revenue	FY2024	$70.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.